Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Atropos Health CEO Dr. Brigham Hyde on closing healthcare’s evidence gap with AI-driven insight

By Brian Buntz | February 14, 2025

Ai generates creation content concepts. Man's hand uses AI icon technology, Marketers education, research, analyze media video streaming online marketing strategies to grow their digital business.

[Adobe Stock]

As the CEO and cofounder of Atropos Health, Dr. Brigham Hyde is focused on closing the “evidence gap” that frequently arises in modern medicine. While healthcare decisions often boil down to detective work, the pursuit of the best data to guide decisions is sometimes hamstrung by limited or partial guidance from clinical trials or established protocols for rare or complex cases. In the following Q&A, Hyde discusses the potential of bridging the evidence gap with emerging AI tools like Deep Research in healthcare and academia while also highlighting their limitations. Below, he offers a concise take on how these tools can assist in healthcare decision-making, potential pitfalls, and where AI might be headed.

What do you make of Deep Research for general academic use?

Hyde: Using tools not specifically built for healthcare raises important concerns. Healthcare data is nuanced and the training matters. For general academic uses, AI has proven to be a useful tool, with human oversight, for rapid research and summarization of publicly available information.

Where do you see general-purpose AI platforms like Deep Research offering value in healthcare?

Hyde: I see general-purpose AI platforms offering significant value in search functions and summarization from publicly available resources on the internet. However, the limitation is that these platforms often lack specific training in healthcare. Their recommendations are often generalized and not specific to patient care, which may lead to errors or misinterpretations when applied to specific patient populations or clinical settings.

Can you speak to the risk of hallucinations in medical questions with DeepSeek?

Hyde: Hallucinations in AI in a healthcare setting can directly impact patient safety. It’s important that AI-generated answers provide sources and that AI users check those sources if the datasets include conflicting, outdated, or unverified information. At Atropos Health, we train our AI models on 300M+ de-identified patient records. We score each data set using our published methodology, RWDS, to ensure that the RWD is high quality. We also subject our solutions to independent evaluation. In an independent study, our healthcare-focused LLM, ChatRWD, outperformed other LLMs when evaluated by independent clinicians, answering 94% of the questions and delivering the best answers 87% of the time. In contrast, competing LLMs such as ChatGPT-4 and Gemini Pro 1.5 offered relevant, evidence-based responses less than 10% of the time.

How do you ensure reliable and secure use of your data, and what concerns do you have about general AI tools meeting these standards?

Hyde: We offer two options for data. The Atropos Evidence Network is a federated model. For customers who want to use their own data, we install GENEVA OS within the customer’s firewall – reducing the need to ship data and the risks associated with that. Some customers choose both – the Atropos Evidence Network and their own data. We recently announced the ability for AI developers to build, test and train AI models on the Atropos Evidence Network. The goal is that the more models trained on high-quality RWD, the more rapid advancements healthcare can make.

Can you speak to the importance of domain expertise and custom tools versus off-the-shelf, more generalized applications for agentic research, particularly in healthcare?

Hyde: Healthcare expertise is critical because medical research and patient care are complex and highly specialized. Off-the-shelf, generalized applications may work well in certain contexts, but when applied to healthcare, they may not have all the data needed to ensure accuracy when it comes to medical treatments.

How do you see the AI agent space evolving in healthcare in the coming 12 months or so?

Hyde: In the next 12 months, I expect rapid advancements in healthcare AI agents, with a growing focus on precision medicine. We will likely see AI tools become more integrated with electronic health records (EHR) systems, enabling real-time data analysis and decision support at the point of care.


Filed Under: machine learning and AI

 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Accelerating science with AI-enhanced cryo-EM workflows
Abstract neural network
Inside IQVIA’s quest to build a multi-agent AI ‘dream team’ to transform clinical trials
Recursion-MIT AI screens thousands of molecules before a single FEP run completes
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE